Materialise NV (MTLS)

Oct 28, 2026

Materialise NV reported Q3 2026 consolidated revenue growth of over 2% year-on-year to 67.7 million Euros, or nearly 5% excluding recent divestitures. The Medical segment led growth with a 10% increase, driven by personalized solutions and new product launches, while Software revenue declined due to cautious customer spending. The company maintained its full-year 2026 revenue and adjusted EBIT guidance, reflecting confidence in its strategic execution, including investments in its CO-AM platform and continued share buyback program.

Oct 28, 2026

Materialise NV reported third-quarter 2026 revenue of €67.67 million, a 2.1% year-over-year increase, or 4.9% excluding recent divestitures. Despite the revenue growth, net profit declined to €1.38 million and adjusted EBITDA decreased to €8.05 million. The company's Medical segment showed strong double-digit growth, while Manufacturing benefited from aerospace and defense markets, and Materialise maintained a net cash position of €82.47 million.

Oct 28, 2026

Materialise NV announced its financial results for the third quarter ended September 30, 2026, reporting a 2.1% increase in total revenue to 67,670 kEUR, or 4.9% excluding recent divestitures. The Materialise Medical segment showed double-digit growth, while the Manufacturing segment, adjusted for divestitures, also saw renewed revenue growth. The company reaffirmed its full-year 2026 revenue and Adjusted EBIT guidance, emphasizing strategic execution, targeted investments, and continued cost control.